Aerie Pharmaceuticals Inc. said late Thursday it was launching a secondary offering of its shares. Aerie shares surged 45% to close at $30.61 Thursday after the drug discovery company announced Wednesday its eye treatment Roclatan performed well in clinical studies. Aerie said it plans a secondary offering of $50 million in shares, with Cantor Fitzgerald as the sole underwriter, to help finance commercialization of its other eye treatment Rhopressa, Japanese clinical trials, and to start work on a manufacturing plant. Aerie shares rose 0.9% to $30.87 after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News